Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Valeric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.64 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.67 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.64 |
| ▸ | PPARG | P37231 | 7/20 | 0.64 |
| ▸ | PPARD | Q03181 | 7/20 | 0.64 |
| ▸ | PPARA | Q07869 | 7/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.64 |
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.64 |
| ▸ | FABP4 | P15090 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | TLR2 | O60603 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.64 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | PDE4A | P27815 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valeric Acid SCHEMBL9561300 | 0.95 | FFAR3 (0.62) | AKR1B1GPR84PPARGPPARDPPARA | |
| Valeric Acid SCHEMBL28060341 | 0.95 | AKR1B1 (0.74) | AKR1B1GPR84PPARGPPARDPPARA | |
| Valeric Acid SCHEMBL2825806 | 0.95 | AKR1B1 (0.74) | AKR1B1GPR84PPARGPPARDPPARA | |
| Valeric Acid SCHEMBL50167 | 0.95 | AKR1B1 (0.74) | AKR1B1GPR84PPARGPPARDPPARA | |
| Valeric Acid SCHEMBL386697 | 0.95 | AKR1B1 (0.74) | AKR1B1GPR84PPARGPPARDPPARA | |
| Hexanoate SCHEMBL4631679 | 0.92 | AKR1B1 (0.80) | AKR1B1GPR84PPARGPPARDPPARA | |
| Hexanoate SCHEMBL27891484 | 0.91 | AKR1B1 (0.70) | AKR1B1GPR84PPARGPPARDPPARA | |
| Palmitic Acid SCHEMBL4630382 | 0.90 | GPR84 (0.81) | AKR1B1GPR84PPARGPPARDPPARA | |
| Nonanoate SCHEMBL4631675 | 0.90 | GPR84 (0.81) | AKR1B1GPR84PPARGPPARDPPARA | |
| Dodecanoate SCHEMBL4631132 | 0.90 | GPR84 (0.81) | AKR1B1GPR84PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9504640-B2 | Modified release formulations of a bupropion salt | VALEANT PHARMACEUTICALS LUXEMBOURG S.Á.R.L. (LU) | 2016-11-29 | — | — | US | disclosed |
| US-20150202147-A1 | Modified Release Formulations Of A Bupropion Salt | VALEANT INTERNATIONAL BERMUDA (BM) | 2015-07-23 | — | — | US | disclosed |
| US-8932628-B2 | Modified release formulations of a bupropion salt | VALEANT INTERNATIONAL BERMUDA (BM) | 2015-01-13 | — | — | US | disclosed |
| US-20140242063-A1 | PHARMACEUTICAL COMPOSITIONS | VALEANT LABORATORIES INTERNATIONAL BERMUDA (BM) | 2014-08-28 | — | — | US | disclosed |
| US-20140170216-A1 | BUPROPION HYDROBROMIDE POLYMORPHS | VALEANT INTERNATIONAL BERMUDA (BM) | 2014-06-19 | — | — | US | disclosed |
| US-20140030249-A1 | Pharmaceutical Compositions | VALEANT INTERNATIONAL BERMUDA (BM) | 2014-01-30 | — | — | US | disclosed |
| US-8604085-B2 | Bupropion hydrobromide polymorphs | VALEANT INTERNATIONAL BERMUDA (BM) | 2013-12-10 | — | — | US | disclosed |
| US-20130266650-A1 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS | JACKSON GRAHAM (BB) | 2013-10-10 | — | — | US | disclosed |
| US-20130059005-A1 | BUPROPION HYDROBROMIDE POLYMORPHS | JPMORGAN CHASE BANK, N.A. | 2013-03-07 | — | — | US | disclosed |
| US-8354453-B2 | Bupropion hydrobromide and therapeutic applications | VALEANT INTERNATIONAL BERMUDA (BM) | 2013-01-15 | — | — | US | disclosed |
| CN-1434108-A | Trigger response composition | ROHM & HAAS (US) | 2003-08-06 | — | — | CN | disclosed |
| EP-1331262-A1 | Triggered response compositions | ROHM AND HAAS COMPANY (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-0612520-B1 | PH-triggered osmotic bursting delivery devices | PFIZER (US) | 2001-07-11 | — | — | EP | disclosed |
| EP-0711146-B1 | OSMOTIC DEVICE HAVING A VAPOR-PERMEABLE COATING | PFIZER (US) | 2000-09-06 | — | — | EP | disclosed |
| US-5827538-A | CONTROLLED RELEASE OF THE WATER-INSOLUBLE CORE AFTER IMBIBEMENT OF WATER VAPOR AND WETTING OF A POROUS WALL OF SEMIPERMEABLE HYDROPHOBIC MEMBRANE IMPERVIOUS TO LIQUID WATER; DRUG DELIVERY | PFIZER INC. (US) | 1998-10-27 | — | — | US | disclosed |
| US-5609590-A | PH-triggered osmotic bursting delivery devices | PFIZER INC. (US) | 1997-03-11 | — | — | US | disclosed |
| EP-0711146-A1 | OSMOTIC DEVICES HAVING VAPOR-PERMEABLE COATINGS | PFIZER INC. (US) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995003033-A1 | OSMOTIC DEVICES HAVING VAPOR-PERMEABLE COATINGS | PFIZER INC. (US) | 1995-02-02 | — | — | WO | disclosed |
| US-5358502-A | PH-triggered osmotic bursting delivery devices | PFIZER INC (US) | 1994-10-25 | — | — | US | disclosed |
| EP-0612520-A2 | PH-triggered osmotic bursting delivery devices | PFIZER INC. (US) | 1994-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202147-A1 | Modified Release Formulations Of A Bupropion Salt | SLC6A2, SLC6A3, SLC6A11 | ESR1 3258/4885AKR1B1 1063/4885GPR84 1012/4885 |
| US-20140170216-A1 | BUPROPION HYDROBROMIDE POLYMORPHS | SLC6A3, GABBR1, SLC6A2 | ESR1 2318/4885AKR1B1 652/4885GPR84 2855/4885 |
| US-20130059005-A1 | BUPROPION HYDROBROMIDE POLYMORPHS | SLC6A3, GABBR1, SLC6A2 | ESR1 2318/4885AKR1B1 652/4885GPR84 2855/4885 |
| US-20140030249-A1 | Pharmaceutical Compositions | HTT, ATXN10, TTR | ESR1 4732/4885AKR1B1 3769/4885GPR84 1137/4885 |
| US-20140242063-A1 | PHARMACEUTICAL COMPOSITIONS | HTT, ATXN10, TTR | ESR1 4732/4885AKR1B1 3769/4885GPR84 1137/4885 |
| US-20130266650-A1 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS | GABBR1, SLC6A2, GABBR2 | ESR1 1997/4885AKR1B1 854/4885GPR84 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.